Content by Inozyme Pharma Inc.

|2 min read

Recombinant Protein Administered to First Infant with ENPP1 Deficiency

Phase 1b trial of INZ-701 aimed to improve quality of life in patients with rare, genetic diseases 
Page 1 of 1